Conv. Plasma
Nigella Sativa

All casirivimab/imdevimab..
Meta analysis
study COVID-19 treatment researchCasirivimab/imdevimabCasirivimab/i.. (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Ventilation 33% Improvement Relative Risk Oxygen therapy 46% Casirivimab/i..  Miyashita et al.  EARLY TREATMENT Is early treatment with casirivimab/imdevimab beneficial for COVID-19? Retrospective 922 patients in Japan Lower need for oxygen therapy with casirivimab/imdevimab (p=0.0044) Miyashita et al., J. Infection and Che.., May 2022 Favors casirivimab/im.. Favors control

Clinical efficacy of casirivimab-imdevimab antibody combination treatment in patients with COVID-19 Delta variant

Miyashita et al., Journal of Infection and Chemotherapy, doi:10.1016/j.jiac.2022.05.012
May 2022  
  Source   PDF   All   Meta
16th treatment shown to reduce risk in March 2021
*, now known with p = 0.000018 from 28 studies, recognized in 42 countries. Efficacy is variant dependent.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments.
Retrospective 461 patients treated with casirivimab/imdevimab in Japan, and 461 matched controls, showing lower oxygen requirements with treatment.
Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for many omicron variants Haars, Liu, Pochtovyi, Sheward, Tatham, VanBlargan.
risk of mechanical ventilation, 33.3% lower, RR 0.67, p = 1.00, treatment 2 of 461 (0.4%), control 3 of 461 (0.7%), NNT 461.
risk of oxygen therapy, 46.4% lower, RR 0.54, p = 0.004, treatment 30 of 461 (6.5%), control 56 of 461 (12.1%), NNT 18.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Miyashita et al., 26 May 2022, retrospective, Japan, peer-reviewed, 6 authors, average treatment delay 4.0 days.
This PaperCasirivimab/i..All
Clinical efficacy of casirivimab-imdevimab antibody combination treatment in patients with COVID-19 Delta variant
MD Naoyuki Miyashita, Yasushi Nakamori, Makoto Ogata, Naoki Fukuda, Akihisa Yamura, Yoshihisa Ishiura
Journal of Infection and Chemotherapy, doi:10.1016/j.jiac.2022.05.012
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Conflicts of interest The authors declare that they have no conflicts of interest. Author's contributions: All the authors conceived the study, participated in its design and coordination and collected and managed the data, including quality control. NM and YN drafted the manuscript, and all authors contributed substantially to its revision. All the authors read and approved the final manuscript. Ethical approval and consent to participate J o u r n a l P r e -p r o o f
Baum, Fulton, Wloga, Copin, Pascal et al., Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies, Science
Bierle, Ganesh, Razonable, Breakthrough COVID-19 and casirivimabimdevimab treatment during a SARS-CoV-2 B1.617.2 (Delta) surge, J Clin Virol
Ghosn, Chaimani, Evrenoglou, Davidson, Graña et al., Interleukin-6 blocking agents for treating COVID-19: a living systematic review, Cochrane Database Syst Rev
Hansen, Baum, Pascal, Russo, Giordano et al., Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail, Science
Marconi, Ramanan, De Bono, Kartman, Krishnan et al., Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebocontrolled phase 3 trial, Lancet Respir Med
O'brien, Forleo-Neto, Musser, Chan, Sarkar, Subcutaneous REGEN-COV antibody combination to prevent Covid-19, N Engl J Med
O'brien, Forleo-Neto, Sarkar, Isa, Hou et al., Effect of subcutaneous casirivimab and imdevimab antibody combination vs placebo on J o u r n a l P r e -p r o o f development of symptomatic COVID-19 in early asymptomatic SARS-CoV-2 infection. A Randomized Clinical Trial, JAMA
Planas, Saunders, Maes, Guivel-Benhassine, Planchais et al., Considerable escape of SARS-CoV-2 Omicron to antibody neutralization, Nature
Siemieniuk, Bartoszko, Ge, Zeraatkar, Izcovich et al., Drug treatments for covid-19: living systematic review and network meta-analysis, BMJ
Takashita, Kinoshita, Yamayoshi, Sakai-Tagawa, Fujisaki et al., Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant, N Engl J Med
Takashita, Kinoshita, Yamayoshi, Sakai-Tagawa, Fujisaki et al., Efficacy of antiviral agents against the SARS-CoV-2 Omicron subvariant BA.2, N Engl J Med Mar, doi:10.1056/NEJMc2201933
Wagner, Griesel, Mikolajewska, Mueller, Nothacker et al., Systemic corticosteroids for the treatment of COVID-19, Cochrane Database Syst Rev
Weinreich, Sivapalasingam, Norton, Ali, Gao et al., REGEN-COV antibody combination and outcomes in outpatients with Covid-19, N Engl J Med
Weinreich, Sivapalasingam, Norton, Ali, Gao et al., REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19, N Engl J Med
Zhu, Zhang, Li, Yang, Song, A novel coronavirus from patients with pneumonia in China, 2019, N Engl J Med
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop